EE181 An Economic Model to Estimate Costs of Cytokine Release Syndrome (CRS) and Neurological Events (NE) Among Patients Treated with Lisocabtagene Maraleucel (LISO-CEL) or Axicabtagene Ciloleucel (AXI-CEL) for Second-LINE (2L) Treatment of ...
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.430
https://www.valueinhealthjournal.com/article/S1098-3015(22)00631-3/fulltext
Title :
EE181 An Economic Model to Estimate Costs of Cytokine Release Syndrome (CRS) and Neurological Events (NE) Among Patients Treated with Lisocabtagene Maraleucel (LISO-CEL) or Axicabtagene Ciloleucel (AXI-CEL) for Second-LINE (2L) Treatment of ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00631-3&doi=10.1016/j.jval.2022.04.430
First page :
Section Title :
Open access? :
No
Section Order :
10375